Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oritavancin. Eli Lilly & Co.

J F Barrett1

  • 1Bristol-Myers Squibb Pharmaceutical Research Institute, Department of Infectious Diseases--Microbiology, Wallingford, CT 06492, USA. John.Barrett@bms.com

Current Opinion in Investigational Drugs (London, England : 2000)
|March 15, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maternal outcomes at 3 months after planned caesarean section versus planned vaginal birth for twin pregnancies in the Twin Birth Study: a randomised controlled trial.

BJOG : an international journal of obstetrics and gynaecology·2015
Same author

Bacterial resistance.

IDrugs : the investigational drugs journal·2005
Same author

Quinolone update.

IDrugs : the investigational drugs journal·2005
Same author

Targets, targets everywhere--so where are the new antibacterial drugs?

IDrugs : the investigational drugs journal·2005
Same author

American Society of Microbiology - 100th General Meeting.

IDrugs : the investigational drugs journal·2005
Same author

Antifungal agents and efflux pump inhibitors.

IDrugs : the investigational drugs journal·2005
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Oritavancin is a promising new glycopeptide antibiotic effective against vancomycin-resistant bacteria, including enterococci. Its development shows potential for treating challenging bacterial infections, even resistant strains.

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Oritavancin (LY-333328) is a novel glycopeptide antibiotic developed by Eli Lilly.
  • It is designed to target vancomycin-resistant bacteria, particularly enterococci.
  • The drug has advanced to Phase III clinical trials.

Purpose of the Study:

  • To evaluate the efficacy of oritavancin against resistant bacterial strains.
  • To explore its potential as a single-agent therapy for antibiotic-resistant enterococci infections.

Main Methods:

  • Clinical trials (Phase III) were initiated in January 2001.
  • Comparative activity assessments against vancomycin and teicoplanin were performed.
  • Bactericidal activity was evaluated.

Related Experiment Videos

Main Results:

  • Oritavancin demonstrates activity comparable to vancomycin and teicoplanin.
  • Crucially, it retains efficacy against glycopeptide-resistant bacterial strains.
  • Bactericidal activity was observed.

Conclusions:

  • Oritavancin shows significant potential for treating infections caused by antibiotic-resistant enterococci.
  • Its ability to overcome glycopeptide resistance makes it a valuable therapeutic candidate.
  • Further research into its mechanism of action, possibly involving glycosyl dimerization and D-Ala-D-Ala binding stabilization, is warranted.